BMS Files Ipilimumab With FDA And EMA, Positioning It For Launch Next Year

If approved, the CTLA-4 inhibitor would be the first new drug for the treatment of metastatic melanoma in over a decade.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet